Eldis

Please note - this is a temporary window. id21 is joining forces with Eldis and therefore the id21 website has been suspended. Soon all id21 content will be available on the Eldis website.

Improving diabetes care in sub-Saharan Africa

The rise in type 2 diabetes is a worldwide epidemic. In sub-Saharan Africa, where diabetes competes with communicable diseases for scarce financial and staff resources, the effects are potentially disastrous. People in this region with type 1 diabetes have a very short life expectancy. What is needed to address the pending crisis?

In Africa, a continent already burdened with the serious problem of communicable diseases such as malaria, HIV and tuberculosis, the incidence of non-communicable diseases such as high blood pressure and diabetes is on the rise. The prevalence of type 1 diabetes is reportedly low (about 35,000 people), due either to a lower incidence, under-diagnosis or misdiagnosis, and prognosis is poor (life expectancy of five years). Meanwhile, an estimated 7 million sub-Saharan Africans had type 2 diabetes in 2000 and this is expected to rise to almost 19 million over the next 30 years.

As the number of people with diabetes rises, the increase in diabetes-related health complications and the need to manage these will put pressure on the health care systems of countries that are already seriously lacking in resources. There are two challenges on this front – to halt the rise in type 2 diabetes related to increasing urbanisation and obesity, and to provide accessible care and medicines for those diagnosed with diabetes.

The International Insulin Foundation examines the barriers to access to diabetes care in sub-Saharan Africa and offers an 11-point action plan for the region. These are based on a number of findings, including:

To improve the lives of patients with both types of diabetes, trained health care workers, a functioning health care system, a functioning referral system, guidelines and the ongoing availability of drugs are needed. Among the actions recommended for sub-Saharan governments are the following:

Source(s):
‘The Diabetes Foundation Report on implementing national diabetes programmes in sub-Saharan Africa: Overview’, International Insulin Foundation: London, by David Beran, 2006 Full document.
‘Diabetes care in sub-Saharan Africa’, The Lancet 368, pages 1689-1695, by David Beran and John S. Yudkin, 2006 Full document.
 

Funded by: The Diabetes Foundation, World Diabetes Foundation, WHO Essential Drugs and Medicines Unit, and Barnett and Sylvia Shine No. 2 Charitable Trust

id21 Research Highlight: 15 March 2007

Further Information:
David Beran
International Insulin Foundation
Diabetes and Cardiovascular Disease Academic Unit
Royal Free and University College Medical School
The Archway Campus
2-10 Highgate Hill
London N19 5LW
UK

Tel: +44 (0) 20 72885347
Fax: +44 (0) 20 72883382
Contact the contributor: david.beran@access2insulin.org

International Insulin Foundation

Other related links:
'Assessing access to insulin in Mali, Mozambique and Zambia'

'Treating diabetes in Ghana: is there a role for traditional medicine?'

'Five years on… Improvements in diabetes care in Trinidad and Tobago'

'Keep it in the family - preventing cardiovascular disease in The Gambia'

'Best of both worlds? Public and private sector care for people with diabetes in Trinidad'

World Diabetes Foundation: Media Backgrounder on diabetes in the developing world (PDF)

World Health Organization Diabetes Programme

Views expressed on these pages are not necessarily those of DfID, IDS, id21 or other contributing institutions. Articles featured on the id21 site may be copied or quoted without restriction provided id21 and originating author(s) and institution(s) are acknowledged. Copyright © 2009 IDS. All rights reserved.

id21 is funded by the UK Department for International Development. id21 is one of a family of knowledge services at the Institute of Development Studies at the University of Sussex. id21 is a www.oneworld.net partner and an affiliate of www.mediachannel.org. IDS is a charitable company, No. 877338.